1. Introduction {#sec1}
===============

Serum uric acid (SUA) is one of the most abundant molecules with antioxidant properties in human blood acting as a free radical scavenger and a chelator of transitional metal ion \[[@B1], [@B2]\]. However, increased SUA is a highly prevalent condition with controversial health consequences. Emerging data has suggested the causative role of elevated UA levels in cardiovascular, respiratory diseases, renal diseases, and metabolic syndrome \[[@B2]--[@B4]\]. Hyperuricemia is a consequence of impaired kidney function and can increase the risk of chronic kidney disease and end-stage renal disease \[[@B5]\]. Low levels of SUA are detrimental to the neurons, while high levels of SUA contribute to inflammation and neuroprotection \[[@B6]\].

Interestingly, it has been hypothesized that SUA may confer protective effects on cancer due to its antioxidant property \[[@B7]\]. However, currently published epidemiological studies on the association between SUA levels and cancer-related incidence and mortality have provided conflicting and inconclusive findings possibly because of different study design, source of controls, sample size, and statistical power. The study by Kuo et al. has suggested that low SUA levels are associated with elevated risk of cancer-related mortality compared with high SUA levels, which implicates a protective role of SUA in cancer \[[@B8]\]. On the contrary, Strasak AM and colleagues have demonstrated that high SUA levels are independently related to increased risk of total cancer mortality \[[@B9]\]. To shed light on understanding the paradoxical role of SUA in the risk of cancer incidence and mortality, we performed this meta-analysis of all currently published studies.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

A comprehensive literature screening from databases of PubMed, Embase, and Web of Science was performed for eligible studies from their inception up to August 12, 2014. We used the following terms: uric acid, serum uric acid, gout, or hyperuricemia; cancer, tumor, or carcinoma; cancer risk, cancer incidence, or cancer mortality. The references of all retrieved studies were also screened for additional papers. There were no language restrictions for literature search.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies were included in our study if they conform to the following inclusion criteria: (1) studies in cohort designs; (2) studies on the relationship between SUA and cancer; (3) studies with data of odds ratio (ORs), relative risks (RRs), or hazard ratios (HRs) with 95% confidence intervals (95% CIs). Studies not related to the risk of cancer incidence and mortality, case reports, reviews, animal studies, and studies with overlapping data were all excluded.

2.3. Data Extraction {#sec2.3}
--------------------

Data were extracted by two investigators independently. Disagreements were resolved by consensus. Relevant data were as follows: first author, year of publication, origins, study designs, specific sites of cancer, cancer types, sex, age, sample size, baseline time, follow-up duration, adjusted factors, and RRs or HRs or ORs with corresponding 95% CIs for the risk of cancer incidence and mortality. Available RRs or HRs or ORs with 95% CIs were extracted based on the highest SUA levels in each included study.

2.4. Statistical Analysis {#sec2.4}
-------------------------

We evaluated the strength for association between SUA levels and cancer by calculating the pooled RRs with 95% CIs. Cochran\'s *Q*-statistic test and *I* ^2^ test were performed to estimate the between-study heterogeneity, and *P* \< 0.05 and *I* ^2^ \> 50% suggested potential heterogeneity across all studies \[[@B10], [@B11]\]. The fixed-effects model by Mantel-Haenszel method was applied when the between-study heterogeneity was insignificant \[[@B12]\]; otherwise, the random-effects model by DerSimonian and Laird method was used \[[@B13]\]. Stratified analyses by sex and specific sites of cancer were also carried out. Sensitivity analysis was performed to assess the influence of single studies. Begg\'s funnel plots and Egger\'s test were adopted to estimate publication bias risk \[[@B14], [@B15]\]. STATA 12.0 software (StataCorp, College Station, TX, USA) was used for all analyses.

3. Results {#sec3}
==========

3.1. Literature Search and Characteristics of All Studies {#sec3.1}
---------------------------------------------------------

We performed a comprehensive literature search in PubMed, Embase, and Web of Science databases for eligible studies. According to the inclusion criteria, 5 independent studies on cancer incidence with 456,053 subjects \[[@B4], [@B18]--[@B16]\] and 12 on cancer mortality with 632,472 subjects \[[@B3], [@B8], [@B9], [@B20]--[@B25]\] were finally included in our study. All included studies were in prospective cohort designs, which were published between 1999 and 2014 ([Table 1](#tab1){ref-type="table"}). Other characteristics including first author, year of publication, sample size, follow-up duration, baseline time, sex, and cancer type were presented in [Table 1](#tab1){ref-type="table"} at length. The study by Hiatt and Fireman estimated roles of SUA in cancer incidence among males and females, respectively, and thus it was regarded as two independent studies \[[@B16]\]. Based on different gender, two other papers on the association between SUA and cancer mortality were also divided into two individual studies, respectively \[[@B3], [@B19]\].

3.2. Association between SUA and the Risk of Cancer Incidence {#sec3.2}
-------------------------------------------------------------

We found that high SUA levels were associated with an increased risk of total cancer incidence by meta-analysis of 5 independent studies (RR = 1.03, 95% CI 1.01--1.05, *P* = 0.007) ([Table 2](#tab2){ref-type="table"}, [Figure 1(a)](#fig1){ref-type="fig"}).

When stratifying analysis by sex, the pooled RRs showed that high SUA levels were significantly related to the risk of cancer incidence among males but not females (for men: RR = 1.05, 95% CI 1.02--1.08, *P* = 0.002; for women, RR = 1.01, 95% CI 0.98--1.04, *P* = 0.512) ([Table 2](#tab2){ref-type="table"}, [Figure 1(a)](#fig1){ref-type="fig"}). However, there was only one relevant study on the cancer incidence risk in relation to SUA among females.

When stratifying analysis by specific sites of cancer, significant relationship between high SUA levels and the risk of lymphoid and hematopoietic system cancers was observed, but not other specific sites of cancer ([Table 2](#tab2){ref-type="table"}). Sensitivity analysis did not materially alter the pooled results mentioned above.

3.3. Association between SUA and the Risk of Cancer Mortality {#sec3.3}
-------------------------------------------------------------

The pooled RRs revealed that individuals with high SUA levels were at an elevated risk of total cancer mortality (RR = 1.17, 95% CI 1.04--1.32, *P* = 0.010) ([Table 2](#tab2){ref-type="table"}, [Figure 1(b)](#fig1){ref-type="fig"}). Such significant association was demonstrated in females rather than males (for females: RR = 1.25, 95% CI 1.07--1.45, *P* = 0.004; for males: RR = 1.13, 95% CI 0.86--1.48, *P* = 0.384) ([Table 2](#tab2){ref-type="table"}, [Figure 1(b)](#fig1){ref-type="fig"}). The between-study heterogeneity was not significant in studies performed among women. Thus, fixed-effects model was used to estimate the role of SUA in cancer mortality among females ([Table 2](#tab2){ref-type="table"}). The combined results were further confirmed by sensitivity analysis.

In stratifying analysis by specific sites of cancer, high SUA levels were found to correlate with an elevated risk of digestive cancers mortality (RR = 1.27, 95% CI 1.08--1.49, *P* = 0.003) ([Table 2](#tab2){ref-type="table"}). No significant association was observed in relation to the mortality of other cancers ([Table 2](#tab2){ref-type="table"}). Sensitivity analysis did not modify the pooled results.

3.4. Publication Bias {#sec3.4}
---------------------

No potential publication bias risk was found in our study, as suggested by both Begg\'s funnel plots and Egger\'s test (Figures [1(c)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"}). Similar findings were demonstrated in both studies related to cancer incidence and studies associated with cancer mortality.

4. Discussion {#sec4}
=============

The current meta-analysis shows the evidence that high SUA levels are associated with increased risk of cancer incidence and mortality. The association between SUA and the risk of cancer-related incidence and mortality differs by gender. Positive association between high SUA levels and total cancer incidence was observed in males but not females. Besides, high SUA levels were associated with an elevated risk of total cancer mortality in females but not males.

To the best of our knowledge, UA is produced from metabolic conversion of either dietary or endogenous purines. The primary sites of excretion of UA are kidney and gut. UA is capable of scavenging free radical and chelating transitional metal ions by preventing peroxynitrite-induced protein nitrosylation, lipid and protein peroxidation, and the inactivation of tetrahydrobiopterin \[[@B2]\]. Nonetheless, studies have also suggested a prooxidant role of UA \[[@B2]\]. Elevated levels of SUA can enhance inflammatory response and contribute to hyperuricemia, gout, cardiovascular, and renal complications. It is particularly interesting since UA plays dual roles as antioxidant and prooxidant. Concerning malignant diseases, SUA has drawn much attention for the past few decades. High cell turnover and tumor lysis syndrome in certain cancers are responsible for increased levels of UA in human serum, implicating potential link between SUA and cancer \[[@B8], [@B26], [@B27]\]. It has been demonstrated that UA can provide an antioxidant defense against oxidant- and radical-caused aging and cancer \[[@B7]\]. Nevertheless, UA has also been reported as an independent risk factor for cancer incidence and mortality in other studies \[[@B9], [@B28]\]. Thus, the precise relationship of SUA with cancer remains obscure and needs further elucidation.

Tobacco smoking is a well-established risk factor of lung cancer. Horsfall and colleagues have found that current smokers with low levels of SUA are more susceptible to lung cancer, which suggests a protective role of SUA and an interaction between SUA and smoking in lung carcinogenesis \[[@B4]\]. Reversely, the study by Strasak et al. has shown that elevated levels of SUA are related to higher risk of several site-specific malignancies, for instance, digestive organs, connective tissue, soft tissue and skin, lung cancer, urinary organs, bone, and hematopoietic cancers \[[@B18]\]. However, no significant association between increased SUA levels and the risk of total cancer or cancers of lung, stomach, colon, rectum, bladder, or hematopoietic system was demonstrated by Kolonel et al. \[[@B17]\]. The contradictory findings may be attributed to diverse methodology, ethnicity, environmental exposures, source of controls, and statistical power. Meta-analysis with large sample size is more powerful in identifying minor association by pooling all currently available publications. A total of 5 independent studies on cancer incidence and 12 on cancer mortality were included in the present meta-analysis. The pooled results suggested that elevated SUA levels were positively associated with the risk of total cancer and lymphoid and hematopoietic system cancers, implicating a risk role of SUA in carcinogenesis. Moreover, gender bias was observed when estimating the relationship between SUA levels and cancer risk, which warranted elucidation in more relevant cohort studies with large sample size.

The effect of SUA levels on cancer mortality seems inconsistent. Taghizadeh et al. reported that higher levels of SUA were related to lower risk of cancer mortality, which supported a protective role of SUA in the risk of cancer mortality \[[@B20]\]. Nonetheless, elevated SUA levels were demonstrated to be an independent risk factor for cancer-related mortality in several other cohort studies \[[@B9], [@B21], [@B25]\]. To shed some light on the controversial findings, we estimated the association between SUA and the risk of cancer mortality by meta-analysis of all currently available data. Statistically significant association was observed between higher SUA levels and increased mortality of total cancer and digestive cancers. Besides, the positive correlation was more significant in females than males. Different amounts of SUA, saturation of UA levels in cancer, and metabolism of SUA may be responsible for the risk discrepancy between women and men with cancer. Interestingly, the significant association was related to digestive cancers, but not other specific sites of cancer, implicating site bias in the relationship between higher SUA levels and cancer mortality. The statistically significant association may be a chance finding in that only one eligible study was included related to the mortality of pancreatic cancer and colorectal cancer, respectively \[[@B3], [@B19]\]. In addition, the inconsistent findings for diverse specific sites of cancer might be attributed to variable number of years for cancer mortality, different study design, sample size, environmental exposures, and genetic background. More studies with high quality are warranted to provide a precise estimate for the role of SUA in cancer-related mortality, particularly with regard to specific sites of malignancies and gender.

5. Limitations {#sec5}
==============

The pooled results should be interpreted with caution due to some limitations in our study. First, significant gender bias was found when assessing the effect of SUA on the risk of cancer incidence and mortality; however, the sample size in each stratified analysis by sex seemed a bit limited. More relevant studies with sufficient statistical power are recommended for further elucidation. Second, a significant interaction between SUA and smoking was demonstrated in the development of cancer \[[@B4]\]. We failed to perform stratified analysis by smoking status for lack of enough available studies published to date. It can be further investigated in more future studies. Last but not least, although no significant publication bias was observed in our study, potential bias might be introduced in that not all included studies were based on the same adjusted factors, such as age, gender, environmental exposures, and ethnicity. Thus, the findings in this meta-analysis should be interpreted seriously.

6. Conclusions {#sec6}
==============

In summary, the present study suggests that elevated SUA levels are related to increased risk of cancer incidence and mortality. However, the precise association between SUA levels and cancer warrants further investigation in more independent studies with high quality in the future.
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![(a) Forest plot for SUA and the risk of cancer incidence; (b) forest plot for SUA and the risk of cancer mortality; (c) Begg\'s funnel plots for the risk of cancer incidence (*P* value for Egger\'s test equal to 0.295); (d) Begg\'s funnel plots for the risk of cancer mortality (*P* value for Egger\'s test equal to 0.354).](MI2015-764250.001){#fig1}

###### 

Characteristics of all studies.

  First author             Year   Study design               Origins    Sample size   Followup (years)   Baseline time   Sex     Cancer
  ------------------------ ------ -------------------------- ---------- ------------- ------------------ --------------- ------- -------------------
  Cancer incidence                                                                                                                
   Horsfall \[[@B4]\]      2014   Prospective cohort study   UK         205,484       5                  2000--2012      Mixed   Lung
   Strasak \[[@B18]\]      2009   Prospective cohort study   Austrian   78,850        12.4               1985--2003      Men     All
   Kolonel \[[@B17]\]      1994   Prospective cohort study   Hawaii     7,889         27                 1965--1968      Men     All
   Hiatt \[[@B16]\]        1988   Prospective cohort study   USA        75,283        9.8                1965--1972      Men     All
   Hiatt \[[@B16]\]        1988   Prospective cohort study   USA        88,547        9.8                1965--1972      Women   All
  Cancer mortality                                                                                                                
   Taghizadeh \[[@B20]\]   2014   Prospective cohort study   Dutch      4,350         38                 1965--1969      Men     All
   Juraschek \[[@B21]\]    2014   Prospective cohort study   Scotland   15,083        22.7               1984--1987      Mixed   All
   Kuo \[[@B8]\]           2013   Prospective cohort study   Taiwan     354,110       9                  2000--2007      Mixed   All
   Strasak \[[@B22]\]      2007   Prospective cohort study   Austrian   28,613        15.2               1985--2005      Women   All
   Strasak \[[@B22]\]      2007   Prospective cohort study   Austrian   83,683        13.6               1985--2005      Men     All
   Jee \[[@B23]\]          2004   Prospective cohort study   Korean     22,698        9                  1992--1996      Men     All
   Colangelo \[[@B3]\]     2002   Prospective cohort study   USA        20,433        26.2               1967--1973      Men     Colorectal cancer
   Colangelo \[[@B3]\]     2002   Prospective cohort study   USA        15,149        26.2               1967--1973      Women   Colorectal cancer
   Tomita \[[@B24]\]       2000   Prospective cohort study   Japanese   49,413        5.4                1975--1982      Men     All
   Gapstur \[[@B19]\]      2000   Prospective cohort study   USA        20,475        25                 1963--1973      Men     Pancreatic cancer
   Gapstur \[[@B19]\]      2000   Prospective cohort study   USA        15,183        25                 1963--1973      Women   Pancreatic cancer
   Mazza \[[@B25]\]        1999   Prospective cohort study   Italy      3,282         12                 Not reported    Mixed   All

###### 

Summary meta-analysis results for the association between SUA levels and cancer.

  Group/subgroup                                    Number    RR (95% CI)         *P* value for pooled analysis   *I* ^2^ (%)   *P* value for heterogeneity analysis
  ------------------------------------------------- --------- ------------------- ------------------------------- ------------- --------------------------------------
  Cancer incidence                                                                                                               
   All                                              456,053   1.03 (1.01--1.05)   0.007                           44.7          0.124
   Men                                              162,022   1.05 (1.02--1.08)   0.002                           53.8          0.115
   Women                                            88,547    1.01 (0.98--1.04)   0.512                           ---           ---
  Specific sites                                                                                                                 
   Any                                              250,569   1.03 (1.01--1.05)   0.006                           57.9          0.068
   Respiratory system and intrathoracic organs      456,053   1.05 (0.93--1.19)   0.448                           67.5          0.015
   Digestive organs                                 266,347   1.08 (0.94--1.25)   0.263                           63.4          0.018
   Urinary organs                                   86,739    1.17 (0.44--3.15)   0.752                           82.3          0.018
   Lymphoid and hematopoietic systems               86,739    1.71 (1.10--2.68)   0.018                           30.0          0.232
   Male genital organs                              162,022   1.06 (1.00--1.13)   0.058                           56.1          0.103
  Cancer mortality                                                                                                               
   All                                              632,472   1.17 (1.04--1.32)   0.010                           65.8          0.001
   Men                                              201,052   1.13 (0.86--1.48)   0.384                           77.5          \<0.001
   Women                                            58,945    1.25 (1.07--1.45)   0.004                           30.0          0.240
  Specific sites                                                                                                                 
   Any                                              561,232   1.17 (1.04--1.32)   0.011                           70.7          0.001
   Respiratory system and intrathoracic organs      116,646   1.08 (0.61--1.91)   0.786                           78.2          0.010
   Digestive organs                                 187,886   1.27 (1.08--1.49)   0.003                           40.1          0.124
   Urinary organs                                   112,296   1.35 (0.88--2.07)   0.172                           0.0           0.681
   Lymphoid and hematopoietic systems               112,296   1.18 (0.82--1.70)   0.364                           0.0           0.837
   Bone, connective tissue, soft tissue, and skin   112,296   0.94 (0.47--1.87)   0.857                           0.0           0.588
   Male genital organs                              88,033    0.51 (0.07--3.85)   0.516                           75.5          0.044
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